Genzyme kept by Jefferies at buy

Genzyme Inc. was maintained by Jefferies & Co. analyst David Windley at a buy rating with a price target on the stock of $83 per share following the company's announcement that it submitted a biologics license application with the FDA for Myozyme, for the treatment of Pompe disease - progressive muscle disease due to an inherited enzyme deficiency. Genzyme shares Friday sank $0.79, or 1.05%, to end at $74.41 on volume of 4,473,785 shares versus the three-month running average of 2,954,690 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.